Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
about
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective studyNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsPulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsThe Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-AnalysisChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerPrevention and management of lung cancer in ChinaClinical experiences with molecular targeted therapy in lung cancer in ChinaMedical management of lung cancer: Experience in ChinaChina Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Predictive biomarkers in precision medicine and drug development against lung cancerManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerTreating advanced non-small-cell lung cancer in Chinese patients: focus on icotinibUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancerSystemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateEpidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.Molecular pathways and therapeutic targets in lung cancerCritical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerClinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2.Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.Fatal interstitial lung disease associated with icotinibSuitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population.Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.Management of egfr tki-induced dermatologic adverse events.Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung CancerCombination of icotinib, surgery, and internal-radiotherapy of a patient with lung cancer severely metastasized to the vertebrae bones with EGFR mutation: a case report.Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in ChinaInsight into early-phase trials for lung cancer in the United StatesEfficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma.Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinomaClinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations
P2860
Q21132047-A2D6A037-D13C-4DE1-824D-F2D5904E2316Q21132357-610DFA5C-13A6-4D90-8771-32F52E47FD62Q26768125-10471CD3-4024-4E4D-BDFE-9401C062BF6FQ26772052-0BBDE947-E1A3-42A5-919C-A28D10F8342FQ26775603-0BBCF636-4352-49EE-9F7E-EA431112F8E6Q26775677-DD392D43-D3BC-4FBE-A104-06EA5D303CF6Q26784298-45DC428B-3A00-424E-A85A-97B9111640BAQ26786585-B4BCADE1-EEE4-4CC2-833B-A987EF9A745AQ26798228-A2D5AF1B-9052-4F7B-9790-7CD61F7A450EQ26798257-43C28A2D-AE53-43B8-BE46-ED9B61266957Q26800148-6547876A-2170-4418-A986-9F4D95D51BAAQ26824536-C34D7B11-DA8E-49E2-A045-614B85C02717Q26865779-4A26C973-02B3-426F-AEE4-A4FC20F5DC1CQ26991969-657C1E1F-13CC-4411-A38B-91E28F91059BQ27022535-9A1E6AF9-8CD7-470E-A54E-86DF4F258C97Q28073920-B1814403-7608-46BF-B223-13201B64B4E3Q28075704-36A370A9-C242-47DA-98D8-27D3FA8C8E2DQ30356434-8181848F-320D-451E-956E-5FAF13523D7DQ33648864-E7714217-C58F-40CB-8960-622764BC2A3AQ33688872-9236EE2C-8CF3-41E5-951B-FC30339A0357Q33710152-3CD6B7C0-58EA-4743-9C49-0E3067A00024Q33779741-74A0F312-708A-40F2-B9DA-A33C99B77A37Q33995172-B33CE741-80AB-49EF-8CB8-DDE69F78E752Q34101040-B7550EF1-989C-4163-AAAE-9896638C7585Q34430535-6FA0D837-0B5A-4FC6-9063-38604CF60C08Q34637855-13C6BB55-D8F2-4724-891C-18DC6ADE670DQ34814528-24DDEC96-65B6-43D7-A431-6435D9C0E73AQ35028752-03D7D31B-B8D2-4C5F-98F2-875D4C0D4A1BQ35188669-83CE1214-DB26-4D5B-BE22-D794D6EB8D50Q35444952-7907CF6A-2C24-448F-A37A-14D786ED280CQ35654703-388A720F-0710-443D-A54D-16960509B0FFQ35694472-DD0CF20C-9979-45B3-80F9-CED951C84D4EQ35810510-F855F9FB-08EE-4668-8593-9C5AF03B3F7EQ35850480-C1C20D22-1894-4E78-AF4E-36922DC90DA0Q35970324-46387D8A-6E2A-47B4-8079-40D12345E8C0Q36121135-5CEE1BAB-5CBE-4A1B-81B3-7CD145BB3C40Q36205327-732D5326-C9D9-41DF-8A21-3CCACAE92B58Q36247866-8167BC2F-275A-4755-8167-E347F39BC10BQ36317627-BE269DF3-4033-4315-86F6-D3BE7FBA08DEQ36477762-CECBDB3D-3C95-47BD-854D-3FB9BCA5B64E
P2860
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@en
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@nl
type
label
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@en
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@nl
prefLabel
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@en
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@nl
P2093
P1433
P1476
Icotinib versus gefitinib in p ...... phase 3 non-inferiority trial.
@en
P2093
Caicun Zhou
Chunhong Hu
Chunxue Bai
Fenlai Tan
Helong Zhang
Jianhua Chen
Jianying Zhou
P304
P356
10.1016/S1470-2045(13)70355-3
P50
P577
2013-08-13T00:00:00Z